Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 4D Molecular Therapeutics Inc (NQ: FDMT ) 9.970 -0.370 (-3.58%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about 4D Molecular Therapeutics Inc < Previous 1 2 3 4 5 Next > 4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate September 19, 2024 4D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its Phase 3 4FRONT study for wet AMD. The Phase 3 study comparing 4D-150 to... Via Benzinga The Latest Analyst Ratings For 4D Molecular Therapeutics September 09, 2024 Via Benzinga FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS for Q2 2024 August 09, 2024 FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session July 18, 2024 Via Benzinga Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights July 18, 2024 Via Benzinga Assessing 4D Molecular Therapeutics: Insights From 7 Financial Analysts June 26, 2024 Via Benzinga Analyst Expectations For 4D Molecular Therapeutics's Future June 07, 2024 Via Benzinga 4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD Candidate July 17, 2024 4D Molecular Therapeutics reports 24-week interim data from its PRISM Phase 2 trial, showing 77% of wet AMD patients injection-free with 4D-150. The trial highlights safety and efficacy in reducing... Via Benzinga Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session July 17, 2024 Via Benzinga Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside June 07, 2024 Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. Via Benzinga 4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) March 01, 2024 Via Benzinga What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics February 07, 2024 Via Benzinga Why Is 4D Molecular (FDMT) Stock Up 85% Today? February 05, 2024 Investors in 4D Molecular Therapeutics and FDMT stock are seeing big gains today, as the stock surges 80% on positive trial results. Via InvestorPlace Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session June 06, 2024 Via Benzinga Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released June 06, 2024 4D Molecular Therapeutics shares interim data from the 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease. Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session June 06, 2024 Via Benzinga FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 09, 2024 FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation April 18, 2024 Via Benzinga Topics ETFs 4D Molecular Therapeutics Outlines Pivotal Development Plans For Cystic Fibrosis, Rare Inherited Disease March 28, 2024 4D Molecular Therapeutics' latest advancements in CF treatment. Get insights into their 4D-710 aerosolized genetic medicine for cystic fibrosis lung disease, including Phase 1/2 AEROW trial updates and... Via Benzinga Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today? February 08, 2024 Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction. Via Benzinga Why 4D Molecular Therapeutics (FDMT) Stock Is Diving February 07, 2024 4D Molecular Therapeutics shares are trading lower by 12.7% Wednesday afternoon. The company announced pricing of an upsized underwritten public offering. Via Benzinga 4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast February 06, 2024 4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70. Via Benzinga Crude Oil Moves Higher; Caterpillar Posts Upbeat Earnings February 05, 2024 U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 200 points on Monday. The Dow traded down 0.53% to 38,450.28 while the NASDAQ fell 0.11% to 15,612.52. The... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session February 05, 2024 Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS... Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session February 05, 2024 Via Benzinga Gold Moves Lower; ISM Services PMI Beats Estimates February 05, 2024 U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday. The Dow traded down 1.04% to 38,253.72 while the NASDAQ fell 0.86% to 15,493.97. The... Via Benzinga Topics Stocks Exposures US Equities Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today? February 05, 2024 4D Molecular Therapeutics data in wet AMD treatment. Phase 2 PRISM trial shows promising results - 89% reduction in anti-VEGF injections, stable visual acuity. Via Benzinga Estée Lauder Posts Upbeat Earnings, Joins ON Semiconductor, Tyson Foods And Other Big Stocks Moving Higher On Monday February 05, 2024 U.S. stocks traded lower, with the Dow Jones falling over 300 points on Monday. Via Benzinga Topics Stocks Exposures US Equities Dow Tumbles 150 Points; McDonald's Sales Miss Views February 05, 2024 U.S. stocks traded lower this morning, with the Dow Jones index falling around 150 points on Monday. Following the market opening Monday, the Dow traded down 0.41% to 38,494.03 while the NASDAQ fell... Via Benzinga Topics Earnings Stocks Exposures Financial US Equities 12 Health Care Stocks Moving In Monday's Pre-Market Session February 05, 2024 Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.